Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

21 Jun, 2017, 08:00 ET Menarini Ricerche to Present the Most Recent Data About the Pre-clinical Development of its Novel ADC MEN1309/OBT076 at the 29th Pezcoller Symposium

Menarini Ricerche and the UK company Oxford BioTherapeutics (OBT) will present the latest data about their novel antibody drug-conjugate (ADC)...


21 Jun, 2017, 08:00 ET Vigilant Biosciences Announces Further Clinical Data in Support of its OncAlert® Oral Cancer Product Line at IFOS ENT World Congress 2017 Symposium and at Annual MASCC Meeting

Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced...


21 Jun, 2017, 08:00 ET NovellusDx Announced Today the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523

NovellusDx announced today the completion of the first phase of an in-vitro study to characterize the functional activity of ERK1/2...


21 Jun, 2017, 07:32 ET Large Peer-Reviewed Prospective Outcomes Study Of Proove Opioid Risk® Shows Positive Patient Benefits And Strong Physician Ratings

Proove® Biosciences, Inc. announces a new peer-reviewed study demonstrating that treatment decisions informed by Proove Opioid Risk® result in...


21 Jun, 2017, 07:05 ET RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant...


21 Jun, 2017, 02:00 ET Menarini Ricerche presenterà i dati più recenti sullo sviluppo preclinico del suo nuovo ADC MEN1309/OBT076 al 29° simposio Pezcoller.

Menarini Ricerche in collaborazione con l'azienda inglese Oxford Biotherapeutics (OBT) presenterà, al 29° simposio Pezcoller, che avrà luogo il...


21 Jun, 2017, 02:00 ET Menarini Ricerche präsentiert auf 29. Pezcoller Symposium die aktuellsten Daten zur präklinischen Entwicklung seines neuartigen ADC MEN1309/OBT076

Menarini Ricerche und die britische Oxford BioTherapeutics (OBT) werden auf dem 29. Pezcoller Symposium, das am 22. und 23. Juni 2017 im...


21 Jun, 2017, 02:00 ET Menarini Ricerche présentera les dernières données sur le développement préclinique de son nouvel ADC MEN1309/OBT076 lors du 29e Symposium Pezcoller

Menarini Ricerche et la société britannique Oxford BioTherapeutics (OBT) présenteront les dernières données sur leur nouveau conjugué...


21 Jun, 2017, 02:00 ET Menarini Ricerche presenta los últimos datos sobre ADC MEN1309/OBT076 en el Simposio Pezcoller

- Menarini Ricerche presentará los datos más recientes sobre el desarrollo preclínico de su nuevo ADC MEN1309/OBT076 en el 29 Simposio Pezcoller...


20 Jun, 2017, 18:57 ET Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes

Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA)...


20 Jun, 2017, 18:48 ET Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved MYDAYIS[TM] (mixed salts of a...


20 Jun, 2017, 13:56 ET SEM Scanner Detects Bedsores Before Visual Diagnosis, Pivotal Study Finds

A wireless handheld scanner detected bedsores developing under the skin earlier than visual inspection of the surface of the skin. This gives...


20 Jun, 2017, 11:29 ET Almac Discovery y Debiopharm International SA anuncian el desarrollo de un nuevo inhibidor Wee-1

- Almac Discovery y Debiopharm International SA anuncian un acuerdo de licencia para el desarrollo de un nuevo inhibidor Wee-1 Almac Discovery...


20 Jun, 2017, 11:00 ET Almac Discovery et Debiopharm International SA annoncent un accord de licence pour le développement d'un nouvel inhibiteur de Wee-1

Almac Discovery (http://www.almacgroup.com/discovery), une société biopharmaceutique axée sur la découverte et l'identification de produits...


20 Jun, 2017, 11:00 ET Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor

Almac Discovery (http://www.almacgroup.com/discovery), a biopharmaceutical company focused on discovering and identifying innovative therapeutics...


20 Jun, 2017, 10:00 ET BioImage-2 Starts: Ultrasound Imaging for Cardiac Risk Prediction Looks at Disease Progression

Mount Sinai Heart and BioImage-2 LLC, today announced start of the BioImage-2 study. The BioImage-2 study investigates the progression of vascular...


20 Jun, 2017, 09:30 ET Green Park Collaborative, National Hemophilia Foundation, McMaster University, Announce Launch of CoreHEM Project

An international team involving dozens of stakeholders from patients and policy makers to payers and government agencies are getting...


20 Jun, 2017, 09:14 ET Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML)

Immune Pharmaceuticals (NASDAQ:IMNP) ("Immune"), a clinical stage biopharmaceutical company, announced today that patient enrollment in a Phase...


20 Jun, 2017, 09:05 ET Data Presentations at European Hematology Association (EHA) 22nd Annual Congress Further Validate SkylineDx Prognostic Tools in Multiple Myeloma

SkylineDx today announced the presentation of new data that validate the use of MMprofiler with SKY92, the company's prognostic tool to risk...


20 Jun, 2017, 09:00 ET Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia

Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), today announced 24-month results...


Most Viewed